United Therapeutics shares rise 1.24% premarket after Egetis Therapeutics received FDA Breakthrough Therapy Designation for tiratricol.

United Therapeutics Corporation rose 1.24% in premarket trading, with Egetis Therapeutics, a pharmaceutical development company, submitting a request for a pre-NDA (Type B) meeting with the U.S. Food and Drug Administration (FDA) to discuss the content and timeline for the New Drug Application (NDA) for tiratricol in the United States. The FDA granted tiratricol Breakthrough Therapy Designation (BTD) in July 2025, which is typically granted at an early stage of development, indicating a positive outlook for the upcoming NDA process.